Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) will release its 2022 fourth quarter and year-end financial results on March 8, 2023, after market close. A conference call and webcast are scheduled for March 9, 2023, at 8:30 AM ET to discuss these results. Investors can join the call by calling 1-877-270-2148 domestically or 1-412-902-6510 internationally. Quoin focuses on developing therapeutic products for rare and orphan diseases, with a pipeline including treatments for conditions like Netherton Syndrome and Epidermolysis Bullosa. For more details, visit their official website.
- Scheduled release of Q4 and year-end financial results, providing key updates to investors.
- Focus on rare and orphan diseases, indicating a commitment to addressing unmet medical needs.
- None.
ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company intends to release its 2022 fourth quarter and year-end financial results after the market closes on Wednesday, March 8, 2023.
The Company will host a conference call and webcast at 8:30am ET on Thursday, March 9, 2023. The call will include a discussion of fourth quarter 2022 and year-end results.
The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).
The live and archived webcast of the call will also be available on the Quoin Pharmaceuticals website under the Investors section: https://investors.quoinpharma.com/news-and-events/events-and-presentations
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
For further information, contact:
Investor Relations
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals release its 2022 financial results?
What time is the Quoin Pharmaceuticals conference call?
How can I listen to the Quoin Pharmaceuticals conference call?
What is the focus of Quoin Pharmaceuticals?
What conditions are targeted by Quoin Pharmaceuticals' pipeline?
